-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
DICE Therapeutics (NASDAQ:DICE) Shares Gap Down to $19.09
DICE Therapeutics (NASDAQ:DICE) Shares Gap Down to $19.09
DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) gapped down before the market opened on Wednesday . The stock had previously closed at $19.09, but opened at $18.70. DICE Therapeutics shares last traded at $19.05, with a volume of 2,472 shares.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on DICE. Stifel Nicolaus started coverage on shares of DICE Therapeutics in a research report on Tuesday, September 6th. They set a "buy" rating and a $37.00 price objective on the stock. HC Wainwright started coverage on shares of DICE Therapeutics in a research note on Monday, July 18th. They set a "buy" rating and a $40.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of DICE Therapeutics in a research note on Wednesday, September 14th. They set an "overweight" rating and a $36.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, DICE Therapeutics currently has a consensus rating of "Buy" and an average target price of $43.33.
Get DICE Therapeutics alerts:DICE Therapeutics Trading Down 2.0 %
The business has a fifty day moving average price of $18.47 and a two-hundred day moving average price of $17.73. The firm has a market capitalization of $701.17 million and a PE ratio of -4.80.
Institutional Investors Weigh In On DICE Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in DICE. Amalgamated Bank acquired a new position in DICE Therapeutics during the first quarter worth approximately $39,000. Prospera Financial Services Inc acquired a new position in DICE Therapeutics during the first quarter worth approximately $39,000. Legal & General Group Plc increased its position in DICE Therapeutics by 265.1% during the second quarter. Legal & General Group Plc now owns 4,764 shares of the company's stock worth $74,000 after buying an additional 3,459 shares during the period. Virtus ETF Advisers LLC increased its holdings in shares of DICE Therapeutics by 18.5% in the second quarter. Virtus ETF Advisers LLC now owns 7,482 shares of the company's stock valued at $116,000 after purchasing an additional 1,166 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of DICE Therapeutics in the second quarter valued at approximately $131,000. Institutional investors and hedge funds own 95.42% of the company's stock.About DICE Therapeutics
(Get Rating)
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
Recommended Stories
- Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) gapped down before the market opened on Wednesday . The stock had previously closed at $19.09, but opened at $18.70. DICE Therapeutics shares last traded at $19.05, with a volume of 2,472 shares.
週三開盤前，Dice治療公司(納斯達克：Dice-Get評級)股價下跌。該股此前收盤報19.09美元，開盤報18.70美元。Dice Treateutics的股票尾盤報19.05美元，成交量為2,472股。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Several research firms have recently issued reports on DICE. Stifel Nicolaus started coverage on shares of DICE Therapeutics in a research report on Tuesday, September 6th. They set a "buy" rating and a $37.00 price objective on the stock. HC Wainwright started coverage on shares of DICE Therapeutics in a research note on Monday, July 18th. They set a "buy" rating and a $40.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of DICE Therapeutics in a research note on Wednesday, September 14th. They set an "overweight" rating and a $36.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, DICE Therapeutics currently has a consensus rating of "Buy" and an average target price of $43.33.
幾家研究公司最近發佈了關於骰子的報告。Stifel Nicolaus在9月6日星期二的一份研究報告中開始報道Dice治療公司的股票。他們為該股設定了“買入”評級和37.00美元的目標價。HC Wainwright於7月18日星期一在一份研究報告中開始報道Dice治療公司的股票。他們為該公司設定了“買入”評級和40.00美元的目標價。最後，坎託·菲茨傑拉德在9月14日星期三的一份研究報告中對Dice治療公司的股票進行了報道。他們為該公司設定了“增持”評級和36.00美元的目標價。六位研究分析師對該股的評級為買入，根據MarketBeat.com的數據，Dice Treeutics目前的共識評級為“買入”，平均目標價為43.33美元。
DICE Therapeutics Trading Down 2.0 %
Dice Treeutics股價下跌2.0%
The business has a fifty day moving average price of $18.47 and a two-hundred day moving average price of $17.73. The firm has a market capitalization of $701.17 million and a PE ratio of -4.80.
該業務的50日移動平均價為18.47美元，200日移動平均價為17.73美元。該公司市值為7.0117億美元，市盈率為-4.80。
Institutional Investors Weigh In On DICE Therapeutics
機構投資者參與Dice Treeutics
About DICE Therapeutics
關於骰子治療公司
(Get Rating)
(獲取評級)
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
Dice Treateutics，Inc.是一家生物製藥公司，建立了各種口服治療候選藥物，用於治療免疫學和其他治療領域的慢性病。其平臺DELSCAPE旨在發現選擇性口服小分子，以與系統生物學一樣有效地調節蛋白質-蛋白質相互作用(PPI)。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免費獲取StockNews.com關於DICE治療(DICE)的研究報告
- 斯蒂爾凱斯的收益説明瞭他重返辦公室的原因嗎？
- 這些機構持有達頓餐飲國際公司的股份
- 這三大股利支付者也擁有強勁的價格增長
- 住房建設的黃金時代已經結束了嗎？
- 天然氣價格繼續回升，這些股票應該會受益
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受DICE治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Dice Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧